By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Investing > Accenture Stock Drops as Earnings Outlook Misses Expectations
Investing

Accenture Stock Drops as Earnings Outlook Misses Expectations

News Room
Last updated: 2023/09/29 at 3:37 AM
By News Room
Share
3 Min Read
SHARE

Accenture
stock fell Thursday after the management consultant and tech company reported revenue that missed Wall Street estimates and provided earnings guidance below consensus.

Accenture
(ticker: ACN) posted fiscal-fourth-quarter earnings of $2.71 a share on revenue of $15.99 billion. Analysts surveyed by FactSet were expecting earnings of $2.65 a share on revenue of $16.07 billion. In the fourth quarter last year, the company reported earnings of $2.60 a share on revenue of $15.42 billion.

Accenture
also said new bookings for the quarter were $16.6 billion, a decrease of 10% from the same period last year.

The company expects fiscal 2024 adjusted earnings of between $11.97 to $12.32 a share. That’s below the FactSet consensus of $12.38 a share.

Accenture also posted fiscal 2023 revenue of $64.1 billion. The company expects revenue growth for fiscal 2024 to be between 2% to 5%, which would be less than Wall Street estimates of $67.66 billion.

Evercore ISI analyst David Togut cut his price target on the stock to $333 from $346 but maintained his Outperform rating. Togut wrote in a research note Thursday that “deteriorating discretionary spending softened bookings, increasing headwinds to FY24E revenue growth.”

William Blair analyst Maggie Nolan also maintained her Outperform rating on the stock without a price target.

“Demand for new small deals remains weak, primarily impacting strategy and consulting and systems integration work,” Nolan wrote in a research note. “However, we are encouraged that Accenture continues to capture demand for large transformational deals, as evidenced by 106 clients in fiscal 2023 with quarterly bookings greater than $100 million.”

Chief Executive Julie Sweet said in a news release that she was “extremely proud” of the company’s financial performance. She also added that “our clients’ generative AI bookings of $300 million in the last six months position us at the heart of the beginning of AI-fueled reinvention.”

William Blair’s Nolan wrote that she was “impressed” with gen AI sales.

Shares of Accenture fell 5% Thursday to $298.80 and were on pace for their largest percentage decrease since December 2022, according to Dow Jones Market Data. The stock was the second-worst performer in the
S&P 500
Thursday. Including Thursday’s performance, the stock has risen 12% this year.

Write to Angela Palumbo at [email protected]

Read the full article here

News Room September 29, 2023 September 29, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Wall Street hits back at Trump’s plan to limit interest on credit cards

Major US banks have lashed out at Donald Trump’s proposal to cap…

Franklin Moderate Allocation Fund Q3 2025 Commentary

Franklin Resources, Inc. is a global investment management organization with subsidiaries operating…

Forget Injections. Now You Can Just Take Pills For Weight Loss

Watch full video on YouTube

Stop paying allowances – teach kids to think like owners

Watch full video on YouTube

Zimmer Biomet Holdings, Inc. (ZBH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Robert MarcusJPMorgan Chase & Co, Research Division Good morning, everyone. I'm Robbie…

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Why Home Builders Are Bouncing Today—and Why Their Stocks Are Good Buys

By News Room
Investing

This Beaten-Down Industrial Stock Wants to Call America Home. Why It’s Time to Buy.

By News Room
Investing

These 8 Dividend Aristocrats Can Protect Your Portfolio in a Downturn

By News Room
Investing

Some Lenders Benefit From SBA’s Troubled Loan Program

By News Room
Investing

Social Security Is in Turmoil. Should You Lock In Benefits Now?

By News Room
Investing

Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.

By News Room
Investing

Opinion: The stock-market selloff isn’t over yet. Here are 4 reasons why.

By News Room
Investing

With Trump’s tariffs paused, ‘Big Three’ automakers may race to build inventories

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?